Ask AI
ProCE Banner Activity

Navigating the Latest Guidelines and Therapeutic Advances in Locally Advanced and Metastatic bladder Cancer 

Slideset

Download this slideset featuring the latest data and expert insights on the current treatment landscape in muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma (mUC). Topics covered include evidence-based strategies for therapy selection, treatment sequencing, adverse event management, and aligning care with patient goals.

Released: February 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc. and Astellas Inc.

Astellas Inc.

Pfizer Inc.

Target Audience

This activity is intended for oncologists, urologists, and other healthcare professionals who care for patients with urothelial carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal first-line therapy for patients with la/mUC based on updated guidelines, clinical data, and patient-specific factors

  • Sequence second- and later-line therapies for patients with la/mUC using evidence-based and biomarker-informed strategies

  • Apply multidisciplinary approaches to manage and monitor treatment-related adverse events

  • Implement shared decision-making and caregiver engagement strategies to support personalized care for patients with la/mUC